Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives
Sacubitril/valsartan represents the first of a new class of drugs able to act as a neprilysin inhibitor and as an angiotensin receptor blocker. This double inhibition has the advantage of concomitantly blocking a pro-fibrotic/pro-hypertrophic mechanism (angiotensin receptor blocker component) while stimulating an anti-fibrotic/anti-hypertrophic mechanism (neprilysin inhibitor component). Furthermore, the novel drug has natriuretic and diuretic properties, better preserves renal function, provides better blood pressure control as compared to renin angiotensin system inhibitors, and improves ventricular-arterial coupling.
Source: International Journal of Cardiology - Category: Cardiology Authors: Mauro Gori, Emilia D'Elia, Michele Senni Tags: Review Source Type: research